Patrick Dillon headshot
PD

Patrick M. Dillon

Associate Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Education
Clinical Fellowship, Hematology & Oncology, University of North Carolina
MD, University of North Carolina at Chapel Hill
Residency, Internal Medicine, University of Virginia
Biography

Patrick Dillon, MD, was born in Charleston, SC and attended Furman University where he majored in biochemistry. He completed medical school at the University of North Carolina at Chapel Hill. Both his internship and residency training were at the University of Virginia in Charlottesville, VA. His oncology fellowship training was completed at the University of North Carolina at Chapel Hill. During his fellowship training, Dillon pursued research into mouse models of human cancer, cell signaling, chemotherapy drug delivery and chemotherapy effects on measures of cellular aging. He also pursued markers of immune privilege in a melanoma cell line. He led three clinical trials while at the University of North Carolina and was trained in clinical trial design.

Dillon specializes in the treatment of breast and skin cancers. His current research focuses on immune modulation for treatment of human cancers. He also leads clinical trials of chemotherapeutic agents for the treatment of breast cancer. He promotes cancer survivorship issues and takes an interest in early and late term side effects of cancer treatments.

In his spare time, Dillon enjoys running, hiking, biking and traveling. His wife is an allergist in Charlottesville.

T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer ¿ A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherap
Source: Virginia Commonwealth University
December 06, 2019 – December 05, 2024
A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Source: Alpha Oncology, Inc.
January 29, 2021 – January 28, 2024
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
Source: Johns Hopkins University
May 01, 2020 – February 28, 2023
SWIFT Trial: Surgical Weight-loss to Improve Functional status Trajectories following Total Knee Arthroplasty
Source: Geisinger Clinic
July 07, 2016 – June 30, 2022
MD-INMD-HO - Dillon - Tolero TP-3654-101
Source: Sumitomo Dainippon Pharma Oncology, Inc.
July 01, 2019 – June 30, 2022
MD-INMD-HO Dillon Seattle Genetics LVA002
Source: Seattle Genetics, Inc.
April 02, 2018 – April 01, 2022
MD-INMD Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer
Source: GlaxoSmithKline LLC
October 20, 2016 – October 19, 2021
Focused Ultrasound Therapy to Augment Antigen Presentation and Immune-Specificity of Checkpoint Inhibitor Therapy with Pembrolizumab for Metastatic Breast Cancer
Source: Merck Sharp & Dohme Corp.
September 08, 2017 – September 07, 2021
MD-RADL-Proteon PAD studies
Source: Proteon Therapeutics, Inc.
May 16, 2016 – May 15, 2019
MD-INMD Phase II Study of Everolimus in Combination with Exemestane vs Everolimus Alone vs Capecitabine in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Breast Cancer after Recurrence or Progression on Prior Letrozol
Source: Novartis Pharmaceuticals Corporation
March 14, 2013 – February 12, 2019
MD-INMD A Phase 2 Study of Docetaxel in Combination with 1-methyl-D-tryptophan (indoximod) in Metastatic Breast Cancer
Source: NewLink Genetics Corporation
December 30, 2013 – January 25, 2019
MD-INMD-HO Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-Risk HER2+ Breast Cancer Patients
Source: Cancer Insight, LLC
February 12, 2015 – September 25, 2018
A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer
Source: Lilly USA, LLC
July 06, 2016 – July 05, 2018
Phase II Study of Dovitinib (TK1258) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
Source: Novartis Pharmaceuticals Corporation
December 05, 2011 – December 27, 2017
MD-INMD Phase III STudy of NKTR-102 in Patients with Metastatic or Locally Advanced Breast Cancer
Source: Nektar Therapeutics
June 13, 2012 – June 30, 2016
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
A Phase 2 Study of BMS-754807
Source: Bristol-Myers Squibb Company
December 19, 2011 – March 31, 2015
MD-INMD HO A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases
Source: University of North Carolina-Chapel Hill
March 22, 2012 – March 21, 2014
  • 2013-2018 Best Doctors in America® List
  • 2015 Bedside Manner Award, Our Health Magazine; First place